SCYNEXIS (SCYNEXIS) Net Margin %

: -337.86% (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. SCYNEXIS's Net Income for the three months ended in Dec. 2023 was $-19.6 Mil. SCYNEXIS's Revenue for the three months ended in Dec. 2023 was $5.8 Mil. Therefore, SCYNEXIS's net margin for the quarter that ended in Dec. 2023 was -337.86%.

The historical rank and industry rank for SCYNEXIS's Net Margin % or its related term are showing as below:

SCYX' s Net Margin % Range Over the Past 10 Years
Min: -44388.43 Med: -4851.36 Max: 47.84
Current: 47.84

SCYX's Net Margin % is ranked better than
98.43% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 3.765 vs SCYX: 47.84

SCYNEXIS Net Margin % Historical Data

The historical data trend for SCYNEXIS's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SCYNEXIS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

-44,388.43

-249.68

-1,233.73

47.84

SCYNEXIS Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-946.78	-2,997.88	93.01	-99.77	-337.86

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SCYNEXIS Net Margin % Distribution

For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Net Margin % distribution charts can be found below:

* The bar in red indicates where SCYNEXIS's Net Margin % falls into.

SCYNEXIS Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

SCYNEXIS's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	67.041	/	140.141
	=	47.84 %

SCYNEXIS's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-19.586	/	5.797
	=	-337.86 %

SCYNEXIS (NAS:SCYX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

SCYNEXIS Net Margin % Related Terms

Thank you for viewing the detailed overview of SCYNEXIS's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

SCYNEXIS (SCYNEXIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » SCYNEXIS Inc (NAS:SCYX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

135A:Germany 135A:Germany

Address

1 Evertrust Plaza, 13th Floor, Jersey City, NJ, USA, 07302 - 6548

Website

https://www.scynexis.com

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains.

Executives

David C Hastings	director	C/O ARBUTUS BIOPHARMA, 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Brian Philippe Tinmouth	director	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Guy Macdonald	director	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02139
Ann Hanham	director	ONE EMBRACADERO CTR, STE 2700, SAN FRANCISCO CA 94111
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Armando Anido	director	80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333
Ivor Macleod	officer: Chief Financial Officer	3201 CARNEGIE AVENUE, CLEVELAND OH 44115-2634
Scott Sukenick	officer: General Counsel	101 HUDSON STREET, SUITE 3610, JERSEY CITY NJ 07302
Marco Taglietti	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Lawrence R Hoffman	officer: Interim CFO	C/O COVALENT GROUP, INC., 1275 DRUMMERS LANE, SUITE 100, WAYNE PA 19087
Christine Coyne	officer: Chief Commercial Officer	1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY NJ 07302-6548
Perceptive Life Sciences Master Fund Ltd	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman	10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Eric Francois	officer: Chief Financial Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713
Gonzalez David Angulo	officer: Chief Medical Officer	C/O SCYNEXIS, INC., 3501 C TRICENTER BOULEVARD, DURHAM NC 27713